Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NON EXCLUSIVE - SOURCING AND SUPPLY AGREEMENT-Nov 2011 is JUST FIXED PRICE FOR SUPPLY where as the Prescription to USE EPOGEN or other alternative is at sole discretion of DOCTORS. Meaning Doctor in Dialysis at Fresenius Medical Care & DaVita Inc can use Epogen on a nonexclusive basis for fixed price for 7 YEARS. Whereas to use EPOGEN or other alternative still remains OPEN.
While understanding Amgen's move (SOURCING AND SUPPLY AGREEMENT-Nov 2011), it is clear that AMGEN does that for following reasons.
1. Fear of Competition from peginesatide- Affymax INC.
Amgen foresee that Dialysis Market ($2.9Billion) would be lost completely for ONCE A MONTH Peginesatide, while Epogen, Amgen's other anemia drug Aranesp and another anemia treatment made by Johnson & Johnson must be taken more frequently. With Omontys, doctors and patients will have access to a once-monthly alternative for the treatment of anemia in adult CKD patients on dialysis
2. Roche Holding start selling similar drugs in generic, or "biosimilar," versions of such erythropoiesis-stimulating agents reach the market.
3. Confuse the market and Buy the time..so that they can process EPOGEN NDA for Once month Indication.
Read this agreement....
This Sourcing and Supply Agreement (this “Agreement”) is made by and between Amgen USA Inc. (“Amgen”), a wholly-owned subsidiary of Amgen Inc., and DaVita Inc. (“Dialysis Center”) to set forth the terms and conditions upon which Dialysis Center Purchasers shall purchase EPOGEN® (Epoetin alfa) and Amgen shall provide discounts and pay rebates to Dialysis Center on EPOGEN. Each of Amgen and Dialysis Center are referred to herein as a “Party” and together as the “Parties”. Amgen Inc. is a party to this Agreement for the purposes set forth in Sections 3.1, 8.2, 9.4, 9.5.1, and 11.14 of this Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meaning set forth in Section 1.
HEART DISEASE
In the area of heart disease, Cytori is sponsoring three European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction (heart attack) and chronic myocardial ischemia (a severe form of coronary artery disease).
Heart disease is the number one cause of death in the U.S., Europe, and the majority of other countries around the world. Advanced heart disease also accounts for many disabilities, lost productivity, and diminished lifestyle. Cytori performed pre-clinical (in the laboratory) studies that suggested a restoration of heart function following the application of adipose-derived stem and regenerative cells (ADRCs). Cytori is conducting two safety and feasibility trials, the APOLLO and PRECISE trials, in the areas of acute heart attack and chronic myocardial ischemia, respectively. Currently, Cytori is enrolling a pivotal European trial, ADVANCE, for acute myocardial infarction.
ADVANCE
Acute Myocardial Infarction (Europe)
>>Learn more on ClinicalTrials.gov
http://www.clinicaltrials.gov/ct2/show/NCT01216995?term=ADVANCE%20Cytori&rank=1
FDA approved today for CYTX Graft 850. If application for Heart Implant Graft is confirmed then CYTX=$100
http://ir.cytori.com/InvestorRelations/releasedetail.cfm?ReleaseID=657752
http://www.denverbreast.com/cytori-puregraft-system.html
Biosante Pharmaceuticals Price / Book Value: 1.833
BPAX Price / Book Value Range, Past 5 Years
Minimum 1.833 Mar 14 2012
Maximum 22.32 Jun 2011
Average 6.406
http://ycharts.com/companies/BPAX/price_to_book_value#series=type:company,id:BPAX,calc:price_to_book_value,,id:BPAX,type:company,calc:price_to_book_value&zoom=5&startDate=&endDate=&format=real&recessions=false
AT PRESENT $57million in cash is the Key,
-TEVA has royalty payment against Bio T GEL is $5 MILLION /Annual + OTHER milestone payment of commercializing product in Market..
-BPAX has option to collect Elestrin Gel payment of $144 million, Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Jazz Pharmaceuticals, BioSante´s licensee.
- Aduro BioTech will pay for GVAX trials Phase II cancer clinical trials, most of which are being conducted in cooperation with The Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, and are sponsored or funded by others at no cost to BioSante
- BioSante also has a licensing agreement with Pantarhei Bioscience B.V. for the development of its patented Pill-Plus™ oral contraceptive. Pantarhei is engaged in several Phase II clinical studies with this product from which BioSante hopes to share additional clinical data later this year.
Read more here: http://www.sunherald.com/2012/03/13/3815...
HGSI- GSK PIPELINE: INITIAL RESULTS OF PHASE 3 TRIALS OF ALBIGLUTIDE FOR TYPE 2 DIABETES EXPECTED MID-2012; ENROLLMENT COMPLETED IN SECOND PHASE 3 TRIAL OF DARAPLADIB FOR CARDIOVASCULAR DISEASE
GSK’s Phase 3 program to evaluate the long-term efficacy, safety and tolerability of albiglutide as monotherapy and add-on therapy for patients with type 2 diabetes mellitus continues to move forward. GSK announced topline results of the first of eight Phase 3 trials in November 2011. The study, known as Harmony 7, was designed to compare once-weekly albiglutide to once-a-day liraglutide. Results showed a reduction in HbA1c from baseline of 0.78% for patients receiving albiglutide compared to a reduction of 0.99% for liraglutide. Although the pre-specified margin of non-inferiority to liraglutide was not met, albiglutide did show a statistically significant reduction in HbA1c from baseline (p<0.001). The most common adverse events observed during this study were nausea (9.9% for abiglutide versus 29.2% for liraglutide) and vomiting (5%for abiglutide versus 9.3% for liraglutide).
GSK’s conclusion after review of the data is that the data support continued progress toward registration as a possible once-weekly treatment for type 2 diabetes. GSK expects initial results from the remaining studies over the course of the next several months, and has stated that it expects to provide an update on albiglutide once a more complete view of the data is available in mid-2012
http://www.hgsi.com/latest/human-genome-sciences-reports-progress-with-commercialization-of-benlysta-and-announces-2012-goals-at-jpmorgan-healthcare-confe.html
http://www.gsk-clinicalstudyregister.com/protocol_comp_list.jsp?compound=Darapladib
ONCE WE CROSS $1 then most likely good stock movements expected.
TLON has FDA-ODAC -Meeting for Marqibo approval on 21st March2012
Agenda
The committee will discuss New Drug Application (NDA) 202497, with the proposed trade name Marqibo (vincristine sulfate liposomes injection), application submitted by Talon Therapeutics, Incorporated. The proposed indication (use) for this product is for the treatment of adult patients with Philadelphia Chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more treatment lines of anti-leukemia therapy.
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm290531.htm
A- Preferred shares and subject to approval by Share Holders meeting on 5th April 2012, proposal amendment date 7th July 2012 exercise date 2015, Upon approval of Marqibo by FDA, This would adjust the investments made by WP for conducting clinical trials, etc etc...
Schedule is out from FDA..
TLON has FDA-ODAC -Meeting for Marqibo approval on 21st March2012
Agenda
The committee will discuss New Drug Application (NDA) 202497, with the proposed trade name Marqibo (vincristine sulfate liposomes injection), application submitted by Talon Therapeutics, Incorporated. The proposed indication (use) for this product is for the treatment of adult patients with Philadelphia Chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more treatment lines of anti-leukemia therapy.
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm290531.htm
Cancer treatment 25-30% is Okey but 60%+additional 1 year data is excellent!!!!!!!!!!!
Guys today's presentation at 3PM is Important.
GVAX- 60% INCREASE in survival + In addition, the IPI/GVAX Pancreas combination demonstrated an increase in one year survival, from 7 percent to 27 percent will proved as underdog for BPAX. May change the future of this company. The fact is Hopkins confirms the data and not BPAX.
This would clear any doubts on Libigel.
60% Survival is excellent by any standards.
Today after presentations Libigel future will be cleared.
DNDN cannot assure 5.5 months survival, Looking at many litigations on Libigel BPAX cannot issue any loose statement on GVAX.
Therefor this has be 100% true. we would have Late Mr.Steve Jobs survived 5.5 months more.
SPPI, DNDN , JAZZ this goes from 0.8 to double figure..
ADAM'S Bashing was PROVED WRONG on all these companies when these companies were traded as Penny Stocks.
- BIO-T-GEL would enter $1.6Billion according to IMS Health, Mkt Segment as........ GEL formulation and NOT PATCH like ABBOTT LABS.
Current methods of administration include testosterone injections, patches and gels. Testosterone injections require large needles, are often painful and not effective for maintaining adequate testosterone blood levels throughout the day. Delivery of testosterone through transdermal patches was developed primarily to promote the therapeutic effects of testosterone therapy without the often painful side effects associated with testosterone injections. Transdermal patches, however, similar to estrogen patches, have a physical presence, can fall off, and can result in skin irritation.
Bio-T- Gel - Testosterone formulated gel products for men are designed to deliver testosterone without the pain of injections and the physical presence, skin irritation and discomfort associated with transdermal patches.
LibiGel — once daily transdermal testosterone gel completed Phase III clinical trials and Special Protocol Assessment (SPA) for the treatment of female sexual dysfunction (FSD).NDA would be by end of 1st Quarter 2012.
Elestrin — once daily transdermal estradiol (estrogen) gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S.
HOLD ON SHORTS are now getting nerves
AMOUNT OF SHORT CAN PAY YOU DIVIDEND 10 TIMES IF YOU HOLD ON..!!!!
SHORT GAME OVER NOW...@.82
Libigel STUDY COMPLETED - FEB 14 2012...
CLINICALTRIALS.GOV
http://www.clinicaltrials.gov/ct2/show/study/NCT00657501?term=biosante&rank=2&show_locs=Y#locn
2Billion$ Mkt Potentials according to BPAX presentation
http://www.biotechduediligence.com/uploads/6/3/6/7/6367956/bpax_slides_5-24-11.pdf
Apple reportedly gives China Mobile a "positive answer" regarding 4G LTE iPhone- whereas ChinaMobile use CLWR 4G LTE
China Mobile has been upfront about its plans for 4G LTE and its desire to have the iPhone on its wireless network. According to Bloomberg, China Mobile Chairman Wang Jianzhou confirmed the wireless carrier has been in talks with Apple about a 4G LTE handset and has received a positive answer. Apple has a compelling reason to get the iPhone on China Mobile - with over 600 million subscribers, it's the world's largest wireless carrier.
http://www.tuaw.com/2011/09/15/apple-reportedly-gives-china-mobile-a-positive-answer-regardin/
CLEARWIRE-CHINA MOBILE they would be world leader by 2012 -4G-LTE technology
China Mobile (NYSE: CHL, HKEx: 0941), the world's largest mobile operator in terms of subscribers, and Clearwire Corporation (NASDAQ: CLWR), a leading provider of 4G wireless broadband services in the United States, today announced a collaboration to accelerate the development of TD-LTE devices. Specifically, the two companies agreed to work together to cultivate a robust device ecosystem that supports multi-mode, multi-band devices with minimum component complexity and cost.
China Mobile and Clearwire both support the global 2.5 GHz spectrum band for 4G deployments along with many other operators around the world. To date, both China Mobile and Clearwire have conducted successful TD-LTE trials and tests using commercially available/production-ready TD-LTE devices from numerous vendors. The two companies will work jointly to further accelerate the time-to-market availability of high volume TD-LTE chipsets and devices that should be commercially available starting in 2012. In addition, the two companies will collaborate to enable worldwide data roaming among TD-LTE, FDD-LTE and other 2G/3G networks.
"The availability and cost of TD-LTE devices are critical success factors for operators to deploy TD-LTE networks," said Mr. Jianzhou Wang, Chairman of China Mobile Communications Corporation. "The cooperation with Clearwire will leverage economies of scale in the two largest markets in the world to speed up the development of TD-LTE devices. We anticipate the widest variety and most cost effective high performance devices - modems, routers, smart phones and tablets - to provide end users with affordable advanced mobile broadband services."
"We expect to launch a next-generation LTE network that will offer more capacity than any other 4G network in the United States," said John Stanton, Executive Chairman of Clearwire. "By working with China Mobile, we fully expect to benefit from a device ecosystem aimed to support billions of potential users worldwide. This unmatched scale should reduce costs and increase choices for our customers in the years ahead."
Today's announcement further supports Clearwire's recent announcement of its intent to add LTE technology to its 4G network. By joining forces on TD-LTE technology, product, deployment and roaming solutions, China Mobile and Clearwire are well positioned to build a viable and competitive TD-LTE ecosystem for the highest demand 4G markets on the globe.
http://www.reuters.com/article/2011/09/14/idUS205304+14-Sep-2011+PRN20110914
SPRINT PARTNER CLEARWIRE WOULD BECOME WORLDS LARGEST 4G LTE OPERATOR WITH CHINA MOBILE
China Mobile (NYSE: CHL, HKEx: 0941), the world's largest mobile operator in terms of subscribers, and Clearwire Corporation (NASDAQ: CLWR), a leading provider of 4G wireless broadband services in the United States, today announced a collaboration to accelerate the development of TD-LTE devices. Specifically, the two companies agreed to work together to cultivate a robust device ecosystem that supports multi-mode, multi-band devices with minimum component complexity and cost.
China Mobile and Clearwire both support the global 2.5 GHz spectrum band for 4G deployments along with many other operators around the world. To date, both China Mobile and Clearwire have conducted successful TD-LTE trials and tests using commercially available/production-ready TD-LTE devices from numerous vendors. The two companies will work jointly to further accelerate the time-to-market availability of high volume TD-LTE chipsets and devices that should be commercially available starting in 2012. In addition, the two companies will collaborate to enable worldwide data roaming among TD-LTE, FDD-LTE and other 2G/3G networks.
"The availability and cost of TD-LTE devices are critical success factors for operators to deploy TD-LTE networks," said Mr. Jianzhou Wang, Chairman of China Mobile Communications Corporation. "The cooperation with Clearwire will leverage economies of scale in the two largest markets in the world to speed up the development of TD-LTE devices. We anticipate the widest variety and most cost effective high performance devices - modems, routers, smart phones and tablets - to provide end users with affordable advanced mobile broadband services."
"We expect to launch a next-generation LTE network that will offer more capacity than any other 4G network in the United States," said John Stanton, Executive Chairman of Clearwire. "By working with China Mobile, we fully expect to benefit from a device ecosystem aimed to support billions of potential users worldwide. This unmatched scale should reduce costs and increase choices for our customers in the years ahead."
Today's announcement further supports Clearwire's recent announcement of its intent to add LTE technology to its 4G network. By joining forces on TD-LTE technology, product, deployment and roaming solutions, China Mobile and Clearwire are well positioned to build a viable and competitive TD-LTE ecosystem for the highest demand 4G markets on the globe.
http://www.reuters.com/article/2011/09/14/idUS205304+14-Sep-2011+PRN20110914
CLEARWIRE WOULD BE WORLDS LARGEST CARRIER-2012
China Mobile (NYSE: CHL, HKEx: 0941), the world's largest mobile operator in terms of subscribers, and Clearwire Corporation (NASDAQ: CLWR), a leading provider of 4G wireless broadband services in the United States, today announced a collaboration to accelerate the development of TD-LTE devices. Specifically, the two companies agreed to work together to cultivate a robust device ecosystem that supports multi-mode, multi-band devices with minimum component complexity and cost.
China Mobile and Clearwire both support the global 2.5 GHz spectrum band for 4G deployments along with many other operators around the world. To date, both China Mobile and Clearwire have conducted successful TD-LTE trials and tests using commercially available/production-ready TD-LTE devices from numerous vendors. The two companies will work jointly to further accelerate the time-to-market availability of high volume TD-LTE chipsets and devices that should be commercially available starting in 2012. In addition, the two companies will collaborate to enable worldwide data roaming among TD-LTE, FDD-LTE and other 2G/3G networks.
"The availability and cost of TD-LTE devices are critical success factors for operators to deploy TD-LTE networks," said Mr. Jianzhou Wang, Chairman of China Mobile Communications Corporation. "The cooperation with Clearwire will leverage economies of scale in the two largest markets in the world to speed up the development of TD-LTE devices. We anticipate the widest variety and most cost effective high performance devices - modems, routers, smart phones and tablets - to provide end users with affordable advanced mobile broadband services."
"We expect to launch a next-generation LTE network that will offer more capacity than any other 4G network in the United States," said John Stanton, Executive Chairman of Clearwire. "By working with China Mobile, we fully expect to benefit from a device ecosystem aimed to support billions of potential users worldwide. This unmatched scale should reduce costs and increase choices for our customers in the years ahead."
Today's announcement further supports Clearwire's recent announcement of its intent to add LTE technology to its 4G network. By joining forces on TD-LTE technology, product, deployment and roaming solutions, China Mobile and Clearwire are well positioned to build a viable and competitive TD-LTE ecosystem for the highest demand 4G markets on the globe.
http://www.reuters.com/article/2011/09/14/idUS205304+14-Sep-2011+PRN20110914
UPDATE:New Makena Injection Policy - COVERED FOR REIMBURSEMENT..
https://www.forwardhealth.wi.gov/kw/pdf/2011-69.pdf
$6 by all means..
Clearwire's spectrum, under a set of pessimistic assumptions, is still
worth around $6 a share. Implicit in that estimate is that the company
finds the short-term funding to be able to ultimately realize that
intrinsic value. And while that spectrum value is of less importance
to both debt and equity investors right now then the company's need to
find funding, I believe that emphasis will likely change dramatically
before the end of the year. Just my opinion, mind you....
http://seekingalpha.com/article/301546-a-q-a-with-clearwire-longs-and...
California Governor Jerry Brown Joins SunEdison at Inauguration Ceremony of New Global Headquarters in California SunEdison Opens Headquarters in Solar-Friendly Belmont, California; Focuses on Long-Term Global Growth
BELMONT, Calif., Oct. 11, 2011 /PRNewswire/ -- SunEdison, a leading global provider of solar energy services and subsidiary of MEMC Electronic Materials (NYSE: WFR), was joined yesterday by California Governor Jerry Brown and other government officials and special guests to recognize the opening of the company's global headquarters in Belmont, California.
SunEdison has more than 340 megawatts of solar energy generation capacity deployed across 500 government, commercial and utility solar energy projects making it the largest solar energy services provider in North America. Along with its experience and proven track record for providing quality service, SunEdison is backed by the resources, research and technology of MEMC, a leader in the design and development of semiconductor and solar energy technologies for more than 50 years.
"Locating the SunEdison headquarters to California, the largest energy market in North America with a longstanding commitment to renewable energy, positions us to support better our customers," said Carlos Domenech, president of SunEdison. "Being in Silicon Valley gives us access to a wider talent and companies that are motivated to solve the supply and demand challenges that electric power faces. California has long been a trendsetter in technology, business innovation and caring for the environment. Being here will help us to make solar a viable and meaningful source of energy."
Governor Brown noted that the addition of the SunEdison headquarters is a great step toward building California from the nation's to the world's leader in solar energy, and showcasing that California is open for business. The Governor also said that California has the resources to help SunEdison grow thanks to the state's ethos of creativity, openness to new ideas, ability to think outside-the-box and a willingness to take risks in order to foster job growth and build a leading renewable energy sector.
Joining Governor Brown and Domenech at the event were Board of Equalization member Betty Yee; Assemblyman Jerry Hill; Senator Leland Yee; and Belmont Mayor Coralin Feierbach.
You will be late everyday on this
http://www.investors.affymax.com/releasedetail.cfm?ReleaseID=598778
Usally 5 months before approval stocks goes to the peak...If Takeda is buying 10million equity the Institutional buying follows.
All indications this might go crazy....
This would be double digit soon...
As part of the agreement, Takeda paid Affymax upfront license fees of
$122 million and purchased $10 million of equity. Takeda also
committed to up to $355 million in clinical and development milestone
payments across renal and oncology indications. In addition, Takeda
funded the first $50 million of third party expenses related to
clinical development of peginesatide. Subsequent to that, the
agreement calls for Affymax to pay 30 percent and Takeda to pay the
remaining 70 percent of all third-party peginesatide development
expenses. Each company is responsible for their own overhead and
personnel related expenses. Once the product is on the market, the
companies will share profits equally in the United States and Takeda
will pay Affymax royalties based on net sales of peginesatide outside
the United States.
http://www.affymax.com/view.cfm/55/Takeda-Collaboration
Keep an eye on Oct 2011 SCIE will rollout Wavestat for Colon Cancer $1 billion market opportunity
SpectraScience has developed a technology platform to instantly determine if tissue is normal, pre-cancer or cancerous, without the need for exploratory biopsy. The system is indicated for use as an adjunct to lower gastrointestinal (GI) endoscopy and is intended for the evaluation of polyps less than 1 cm in diameter that the physician has not already elected to remove. The device is used in deciding which polyps should be removed and submitted for histological examination.The Company has received its first FDA approval to market its proprietary and patented optical biopsy system.
-- Planned launch of WavSTAT IV, with key enhancements designed to
improve results and provide for easier use, in October, at UEGW
(United European Gastroenterology Week) held this year in Stockholm,
Sweden.
-- Expansion of sales and marketing strategy to a two-pronged approach,
rolling out with initial regional distribution partnerships for the
WavSTAT IV colon cancer diagnostic in key European markets, and
working towards strategic global distribution partnership(s) which can
be leveraged to address the $1 billion market opportunity for its
single-use optical biopsy forceps. In the future, SpectraScience will
expand its partnership(s) opportunities to address diagnosis of other
kinds of cancer through the use of rigid endoscopy and fine needle
aspiration.
Keep an eye on Oct 2011 SCIE will rollout Wavestat for Colon Cancer $1 billion market opportunity
SpectraScience has developed a technology platform to instantly determine if tissue is normal, pre-cancer or cancerous, without the need for exploratory biopsy. The system is indicated for use as an adjunct to lower gastrointestinal (GI) endoscopy and is intended for the evaluation of polyps less than 1 cm in diameter that the physician has not already elected to remove. The device is used in deciding which polyps should be removed and submitted for histological examination.The Company has received its first FDA approval to market its proprietary and patented optical biopsy system.
-- Planned launch of WavSTAT IV, with key enhancements designed to
improve results and provide for easier use, in October, at UEGW
(United European Gastroenterology Week) held this year in Stockholm,
Sweden.
-- Expansion of sales and marketing strategy to a two-pronged approach,
rolling out with initial regional distribution partnerships for the
WavSTAT IV colon cancer diagnostic in key European markets, and
working towards strategic global distribution partnership(s) which can
be leveraged to address the $1 billion market opportunity for its
single-use optical biopsy forceps. In the future, SpectraScience will
expand its partnership(s) opportunities to address diagnosis of other
kinds of cancer through the use of rigid endoscopy and fine needle
aspiration.
ClinicalTrials.gov processed this record on September 28, 2011
This is NASDAQ stock not pink sheet...Just a reminder
http://www.clinicaltrials.gov/ct2/show/NCT00875108?term=biodel&rank=1
FDA shows Biodel completed Drug: VIAject™ Phase-III trial
An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus
This study has been completed.
http://www.clinicaltrials.gov/ct2/show/NCT00875108?term=biodel&rank=1
From $18 ...0.75 Linjeta approval
Linjeta is a highly effective treatment for diabetes; both type 1 and
type 2. It has been shown to go to work faster and to control blood
glucose levels better than both Humulin and Humalog.
Linjeta passes primary and secondary endpoints in phase III trials…
Due to the fact that Linjeta is classified as a new formulation of an
existing therapy, namely human insulin, Linjeta’s phase III trials
were designed to prove non-inferiority to the traditional therapy.
This allows Biodel to pursue a 505(b)(2) approval path which saves the
company time and money over traditional 505(b)(1) approvals.
Ultimately, the FDA will have to decide if the uncertainty is to be
resolved before Linjeta goes on the market or after.
Due to the non-inferiority in mean HbA1c reduction in most patient
populations (and superiority in terms of weight gain and hypoglycemic
events), I believe the FDA will lean towards approval. I see no reason
1) why Linjeta should be delayed for the type 2 patient populations
where everything was fine and 2) why Linjeta should be sent back for
more trials in type 1 diabetes where the outcome is virtually assured
ahead of time (assuming the samples are kept cold this time around).
Counterfeit Electronic Components
in the U.S. Supply Chain
Summary of a report by
The Office of Technology Evaluation,
Bureau of Industry and Security,
U.S. Department of Commerce.
http://www.rocelec.com/webContent/Rochester-Summary-of-DoD-CounterfeitElectronics-Report.pdf
WFR highly undervalued stock..Bloomberg report..
http://www.bloomberg.com/news/2011-09-20/u-s-solar-power-rises-69-percent-led-by-commercial-projects.html
Manufacturing Plants :
Chonan, South Korea
Hsinchu, Taiwan
Ipoh, Malaysia
Kuala Lumpur, Malaysia
Kuching, Malaysia
Merano, Italy
Novara, Italy
Pasadena, TX USA
Portland, OR USA
St. Peters, MO USA
Sherman, TX USA
Reason for Insider buying ..SAMSUNG 200 billion Joint venture Investment with MEMC by 2013
Samsung Fine Chemicals Co. agreed with MEMC Electronic Materials Inc., a U.S.-based maker of silicon wafers, to set up an equally owned venture for a polysilicon plant in South Korea.
The two companies will build the facility on an existing Samsung Fine Chemicals property in Ulsan, according to an e- mailed statement issued jointly.
The plant, which is expected to start operating in 2013, will have an initial capacity of 10,000 metric tons annually, according to the statement. The cost of the facility wasn’t disclosed.
Samsung Fine Chemicals will invest about 200 billion won ($179 million) in the venture, it said today in a separate regulatory filing.
HIV DRUG FROM ADVENTRX WILL BE GAME CHANGER
http://www.adventrx.com/demos/Animation_HIVLifecycle.swf